Navigation Links
NuvOx Pharma Begins Clinical Trial to Treat Brain Cancer
Date:8/7/2014

Tucson, AZ (PRWEB) August 07, 2014

NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer.

Glioblastoma multiforme (GBM), according to the Central Brain Tumor Registry, affects about 10,300 patients per year in the US. Average survival is only about 12-months following standard therapy, which involves surgery followed by radiation and chemotherapy. GBM, like many other forms of cancer, is known to have low oxygen (hypoxia). Hypoxia adversely affects the response of tumors to radiation therapy and NVX-108 has been shown to raise tumor oxygen levels and improve the response to radiation therapy. The clinical trial is being performed at Monash University in Melbourne Australia. GBM patients who have residual tumor after surgery are receiving an IV dose of NVX-108 during each of the 30 fractions of radiation over a 6-week period. Up to about 25 patients will be treated in the trial. The primary end-point of the trial is safety, but the study will also determine the recommended dose for the drug and provide data on the 6-month survival of the patients. After completion of the trial NuvOx plans to file an investigational new drug application with the FDA and perform a Phase IIb trial in the US.

“We are very excited about moving NVX-108 into the first therapeutic trial. The parent compound, dodecafluoropentane, was previously studied as a contrast agent and was shown to be safe. Due to market considerations it was never launched as a contrast agent. We own that regulatory data and the FDA has agreed that we can reference it in support of clinical development to treat cancer,” said Evan Unger, MD, President and CEO of NuvOx.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12071710.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System
2. Sanuvox Releases the Aseptix Dual UV Sterilization System to Help Reduce Nosocomial (HAI) Infections in Hospital Environments
3. URAC Seeks Public Comments on Revised Specialty Pharmacy and Mail Service Pharmacy Accreditation Standards and Measures
4. Good Neighbor Pharmacy’s 2014 ThoughtSpot Inspires Independent Pharmacists to Transform Their Businesses
5. Harry Race Pharmacy Named 2014 Good Neighbor Pharmacy of the Year
6. Community pharmacist intervention boosts drug adherence, reduces health-care costs
7. Pharmaceuticals Wholesaling in Australia Industry Market Research Report Now Updated by IBISWorld
8. West Coast University Launches New Doctorate of Pharmacy Program
9. PharmaVOICE Honors Five PHCG Leaders Among 100 Healthcare Visionaries
10. US Pharmaceutical Packaging Products Worth $22.1 Billion by 2018 Says a New Research Report at LifeScienceIndustryResearch.com
11. Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: